SCHEMBL4459711

SCHEMBL4459711

CC(C)(C)OC(=O)[C@@H](N)CSC(c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.65

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 19/20 0.65
DNMT1 P26358 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29635035 1.00 KIF11 (0.65) KIF11DNMT1
SCHEMBL5996941 1.00 KIF11 (0.65) KIF11DNMT1
Hydrochloric Acid SCHEMBL25242234 0.99 KIF11 (0.64) KIF11DNMT1
Hydrochloric Acid SCHEMBL4459708 0.99 KIF11 (0.64) KIF11DNMT1
Hydrochloric Acid SCHEMBL4459715 0.99 KIF11 (0.64) KIF11DNMT1
SCHEMBL30745107 0.90 KIF11 (0.64) KIF11DNMT1
SCHEMBL8036028 0.89 KIF11 (0.60) KIF11DNMT1
SCHEMBL12872399 0.85 KIF11 (0.85) KIF11DNMT1
SCHEMBL3439368 0.85 KIF11 (0.85) KIF11DNMT1
SCHEMBL9137501 0.85 KIF11 (0.85) KIF11DNMT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250042939-A1 PREPARATION METHOD FOR OXIDIZED GLUTATHIONE AND CRYSTAL FORM AND IMPURITY THEREOF SHENYANG XINGQI PHARMACEUTICAL CO., LTD. (CN) 2025-02-06 US claimed
EP-4455156-A1 PREPARATION METHOD FOR OXIDIZED GLUTATHIONE AND CRYSTAL FORM AND IMPURITY THEREOF Shenyang Xingqi Pharmaceutical Co., Ltd. (CN) 2024-10-30 EP claimed
WO-2023116664-A1 PREPARATION METHOD FOR OXIDIZED GLUTATHIONE AND CRYSTAL FORM AND IMPURITY THEREOF 沈阳兴齐眼药股份有限公司 2023-06-29 WO claimed
EP-4306530-B1 SILANE-CONTAINING CONDENSED CYCLIC DIPEPTIDE COMPOUND, PRODUCTION METHOD THEREFOR, AND METHOD FOR PRODUCING POLYPEPTIDE COMPOUND USING SAME CHUBU UNIV EDUCATIONAL FOUNDATION (JP) 2026-04-01 EP disclosed
US-20250326798-A1 Synthetic Process for Production of Modified GCC Receptor Agonists IRONWOOD PHARMACEUTICALS INC (US) 2025-10-23 US disclosed
US-20250042939-A1 PREPARATION METHOD FOR OXIDIZED GLUTATHIONE AND CRYSTAL FORM AND IMPURITY THEREOF SHENYANG XINGQI PHARMACEUTICAL CO., LTD. (CN) 2025-02-06 US disclosed
EP-4455156-A1 PREPARATION METHOD FOR OXIDIZED GLUTATHIONE AND CRYSTAL FORM AND IMPURITY THEREOF Shenyang Xingqi Pharmaceutical Co., Ltd. (CN) 2024-10-30 EP disclosed
EP-4436980-A1 SYNTHETIC PROCESS FOR PRODUCTION OF MODIFIED GCC RECEPTOR AGONISTS Ironwood Pharmaceuticals, Inc. (US) 2024-10-02 EP disclosed
CN-118591551-A Synthetic methods for producing modified GCC receptor agonists 硬木药品公司 2024-09-03 CN disclosed
US-20240209020-A1 REACTION AGENT FOR AMIDE REACTION AND METHOD FOR PRODUCING AMIDE COMPOUND USING SAME CHUBU UNIVERSITY EDUCATIONAL FOUNDATION (JP) 2024-06-27 US disclosed
US-20240182517-A1 SILANE-CONTAINING CONDENSED CYCLIC DIPEPTIDE COMPOUND, PRODUCTION METHOD THEREFOR, AND METHOD FOR PRODUCING POLYPEPTIDE COMPOUND USING SAME CHUBU UNIVERSITY EDUCATIONAL FOUNDATION (JP) 2024-06-06 US disclosed
WO-2022190486-A1 SILANE-CONTAINING CONDENSED CYCLIC DIPEPTIDE COMPOUND, PRODUCTION METHOD THEREFOR, AND METHOD FOR PRODUCING POLYPEPTIDE COMPOUND USING SAME 学校法人中部大学 2022-09-15 WO disclosed
EP-4053101-A1 REACTION AGENT FOR AMIDE REACTION AND METHOD FOR PRODUCING AMIDE COMPOUND USING SAME Chubu University Educational Foundation (JP) 2022-09-07 EP disclosed
EP-3779449-B1 DYNAMIC COMBINATORIAL LIBRARY BASED ON PSEUDOPEPTIDES AND ITS USE FOR THE DETECTION OF CYSTEINE AND OTHER BIOTHIOLS CONSEJO SUPERIOR INVESTIGACION (ES) 2022-02-23 EP disclosed
WO-2009151744-A1 S-NITROSOMERCAPTO COMPOUNDS AND RELATED DERIVATIVES GALLEON PHARMACEUTICALS, INC. (US) 2009-12-17 WO disclosed
US-20060281926-A1 Synthesis of 2-alkylcysteine via phase transfer catalysis GIMI RAYOMAND H 2006-12-14 US disclosed
US-7115769-B2 Synthesis of 2-alkylcysteine via phase transfer catalysis GENZYME CORPORATION (US) 2006-10-03 US disclosed
EP-1529037-A2 SYNTHESIS OF 2-ALKYLCYSTEINES, 2-(HYDROXYLATED PHENYL)-4-ALKYLTHIAZOLINE-4-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF Genzyme Corporation (US) 2005-05-11 EP disclosed
US-20030236404-A1 Synthesis of 2-alkylcysteine via phase transfer catalysis GENZYME CORPORATION 2003-12-25 US disclosed
WO-2003097622-A2 SYNTHESIS OF 2-ALKYLCYSTEINES, 2-(HYDROXYLATED PHENYL)-4-ALKYLTHIAZOLINE-4-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF GENZYME CORPORATION (US) 2003-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236404-A1 Synthesis of 2-alkylcysteine via phase transfer catalysis DIMT1, ICMT, CNDP2 KIF11 4699/4885DNMT1 1291/4885
US-20250326798-A1 Synthetic Process for Production of Modified GCC Receptor Agonists GNRHR, SCTR, GIPR KIF11 2319/4885DNMT1 4278/4885
US-20250042939-A1 PREPARATION METHOD FOR OXIDIZED GLUTATHIONE AND CRYSTAL FORM AND IMPURITY THEREOF GPX4, GPX1, GSTM2 KIF11 3253/4885DNMT1 1313/4885
US-20240209020-A1 REACTION AGENT FOR AMIDE REACTION AND METHOD FOR PRODUCING AMIDE COMPOUND USING SAME NAAA, FAAH, FAAH2 KIF11 2232/4885DNMT1 4185/4885
US-20240182517-A1 SILANE-CONTAINING CONDENSED CYCLIC DIPEPTIDE COMPOUND, PRODUCTION METHOD THEREFOR, AND METHOD FOR PRODUCING POLYPEPTIDE COMPOUND USING SAME VIP, NGLY1, NPR1 KIF11 347/4885DNMT1 2764/4885
US-20060281926-A1 Synthesis of 2-alkylcysteine via phase transfer catalysis DIMT1, ICMT, CNDP2 KIF11 4699/4885DNMT1 1291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.